5 Buy-Rated Stocks with Latest Insider Purchases

Page 1 of 5

This article presents an overview of 5 Buy-Rated Stocks with Latest Insider Purchases. For a detailed overview of such stocks read our article, 10 Buy-Rated Stocks with Latest Insider Purchases.

5. Oncternal Therapeutics Inc (NASDAQ:ONCT)

Average Analyst Price Target: $31.33

Upside Potential: 252%

Robert James Wills, a director at Oncternal Therapeutics Inc (NASDAQ:ONCT), bought 3,086 shares of Oncternal Therapeutics Inc (NASDAQ:ONCT) at $8.96 per share. The total value of this transaction was $27,655. The transaction took place on April 8. Since then the stock is up 3%.

As of the end of the fourth quarter of 2023, four hedge funds tracked by Insider Monkey reported owning stakes in the oncology-focused biotech company Oncternal Therapeutics Inc (NASDAQ:ONCT). Over the past one year the stock has gained about 60% in value.

Page 1 of 5